[Skip to Content]
[Skip to Content Landing]
Views 6,704
Citations 0
News From the Food and Drug Administration
December 3, 2019

Clarithromycin-Resistant H pylori Faces New Foe

JAMA. 2019;322(21):2068. doi:10.1001/jama.2019.19479

The FDA has approved a combination drug for Helicobacter pylori infection that’s designed to address high rates of resistance to standard clarithromycin-based treatment, according to manufacturer RedHill Biopharma Ltd of Tel Aviv, Israel. In 2017, the World Health Organization designated the need for new antibiotics against H pylori as a high priority.